Brainstorm Cell Therapeutics Inc. (BCLI) At $4.43 Forms Bottom; Nasdaq Premium Income & Growth Fund (QQQX) Has 1.11 Sentiment

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Logo

Nasdaq Premium Income & Growth Fund Inc (QQQX) investors sentiment decreased to 1.11 in 2018 Q1. It’s down -0.39, from 1.5 in 2017Q4. The ratio turned negative, as 21 investment professionals opened new and increased positions, while 19 sold and decreased their equity positions in Nasdaq Premium Income & Growth Fund Inc. The investment professionals in our database reported: 5.17 million shares, up from 5.08 million shares in 2017Q4. Also, the number of investment professionals holding Nasdaq Premium Income & Growth Fund Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 12 Increased: 15 New Position: 6.

Brainstorm Cell Therapeutics Inc. (BCLI) formed multiple bottom with $4.12 target or 7.00% below today’s $4.43 share price. Brainstorm Cell Therapeutics Inc. (BCLI) has $84.66 million valuation. The stock decreased 3.70% or $0.17 during the last trading session, reaching $4.43. About 138,594 shares traded or 2.00% up from the average. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has risen 14.11% since June 13, 2017 and is uptrending. It has outperformed by 1.54% the S&P500. Some Historical BCLI News: ; 21/03/2018 – BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board; 09/03/2018 – BrainStorm Cell Therapeutics Short-Interest Ratio Up to 32 Days; 08/03/2018 BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017; 25/05/2018 – BrainStorm Cell Therapeutics Issues Statement on “Right to Try” Legislation; 28/03/2018 – BrainStorm Cell Therapeutics’ Phase 3 Trial of NurOwn in ALS Now Open to Canadian Patients; 28/03/2018 – BrainStorm Cell Therapeutics’ Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients; 14/05/2018 – Brainstorm Cell Therptcs 1Q Loss/Shr 12c; 01/05/2018 – BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference; 22/04/2018 – DJ Brainstorm Cell Therapeutics Inc, Inst Holders, 1Q 2018 (BCLI); 13/03/2018 – Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer

Among 2 analysts covering Brainstorm Cell Therapeutics (NASDAQ:BCLI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Brainstorm Cell Therapeutics has $14 highest and $5.0 lowest target. $10’s average target is 125.73% above currents $4.43 stock price. Brainstorm Cell Therapeutics had 6 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) earned “Buy” rating by Maxim Group on Wednesday, August 16. The firm has “Buy” rating by Maxim Group given on Tuesday, June 13. On Wednesday, August 12 the stock rating was maintained by Maxim Group with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Tuesday, May 15. The rating was maintained by Maxim Group with “Buy” on Tuesday, December 22. The stock of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has “Buy” rating given on Friday, July 21 by Maxim Group.

Analysts await Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report earnings on August, 13. They expect $-0.14 earnings per share, down 133.33% or $0.08 from last year’s $-0.06 per share. After $-0.12 actual earnings per share reported by Brainstorm Cell Therapeutics Inc. for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.